Cargando…
Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we d...
Autores principales: | Ruzic, Dusan, Ellinger, Bernhard, Djokovic, Nemanja, Santibanez, Juan F., Gul, Sheraz, Beljkas, Milan, Djuric, Ana, Ganesan, Arasu, Pavic, Aleksandar, Srdic-Rajic, Tatjana, Petkovic, Milos, Nikolic, Katarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785542/ https://www.ncbi.nlm.nih.gov/pubmed/36559094 http://dx.doi.org/10.3390/pharmaceutics14122600 |
Ejemplares similares
-
Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma
por: Djokovic, Nemanja, et al.
Publicado: (2023) -
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
por: Ruzic, Dusan, et al.
Publicado: (2022) -
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
por: Beljkas, Milan, et al.
Publicado: (2023) -
1-Benzhydryl-4-(4-chlorophenylsulfonyl)piperazine
por: Girisha, H. R., et al.
Publicado: (2008) -
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
por: Gagic, Zarko, et al.
Publicado: (2020)